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Nasopharyngeal carcinoma (NPC) is an endemic disease in
Southeast Asia, Taiwan and Southern China. The majority of cases
involve Epstein–Barr virus-related non-keratinizing carcinoma,
including differentiated and undifferentiated subtypes (Shan-
mugaratnam et al, 1991). The local control rate of NPC after
radiation has been higher than 70% but the distant metastasis rate
has been 20–35% at 5 years (Huang et al, 1985; Teo et al, 1989;
Lee et al, 1992). When metastases occur, most of these patients
succumb within months, especially those with liver and/or lung
metastases (Hsu et al, 1983). Combination of cisplatin and 5-fluo-
rouracil (5-FU) (PF) has generally been regarded as the treatment
of choice. The response rate of metastatic NPC to PF has been
around 60% (Decker et al, 1983; Boussen et al, 1991; Choo et al,
1991; Cvitkovic et al, 1991; Mahjoubi et al, 1992; Gebbia et al,
1993; Su et al, 1993; Chi et al, 1994, 1995; Yeo et al, 1996;
Fountzilas et al, 1997).
However, stomatitis, the dose-limiting toxicity, has been very
severe and common, possibly because of prolonged 5-FU infusion
and prior irradiation (Dreyfuss et al, 1990; Vokes et al, 1990).
Chronic toxicities including ototoxicity, nephrotoxicity and neuro-
toxicity, related to repeated use of high dose cisplatin also become
dose-limiting, especially for cases with long-term survival. In
addition, patients have to be hospitalized during treatment because
of the required 120 h infusion of 5-FU. Outpatient-based therapy
with less toxicity and response rates equivalent to or better than PF
is urgently needed to improve the quality of life of patients with
metastatic NPC.
Mitomycin C has been demonstrated to be synergic with
cisplatin in vitro (Teicher et al, 1985; Durand, 1989) and is prefer-
entially activated under hypoxic conditions (Rockwell et al, 1982),
which are believed to exist in large tumours. In two studies, mito-
mycin C increased the response rate significantly when added to
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Summary The combination of cisplatin and 5-fluorouracil (5-FU) (PF) is the most popular regimen for treating metastatic nasopharyngeal
carcinoma (NPC) but it is limited by severe stomatitis and chronic cisplatin-related toxicity. A novel approach including induction with
mitomycin C, doxorubicin and cisplatin (MAP) and subsequent maintenance with weekly 5-FU and leucovorin (FL) were designed with an aim
to reduce acute and chronic toxicity of PF. Thirty-two patients of NPC with measurable metastatic lesions in the liver or lung were entered into
this phase II trial. Mitomycin C 8 mg m–2, doxorubicin 40 mg m–2 and cisplatin 60 mg m–2 were given on day 1 every 3 weeks as initial
induction. After either four courses or remission was achieved, patients received weekly dose of 5-FU 450 mg m–2 and leucovorin 30 mg m–2
for maintenance until disease progression. With 105 courses of MAP given, 5% were accompanied by grade 3 and 0% were accompanied by
grade 4 stomatitis. The dose-limiting toxicity of MAP was myelosuppression. Forty per cent of courses had grade 3 and 13% of courses had
grade 4 leukopenia. No grade 3 or 4 cisplatin-related toxicity was observed. The overall response rate was 94% (95% confidence interval (CI)
84.9–100%) with a complete response rate (CR) of 6% (95% CI: 0–15.2%) and a good partial response (PR) rate of 28% (95% CI
11.7–44.6%), which was optionally defined as observance of only equivocal lesion identifiable under imaging study. Twenty-seven cases
entered weekly FL maintenance phase. The median duration of maintenance with weekly FL was 38 weeks (8–91 weeks). There was no
grade 3 or 4 toxicity noted during weekly FL. The median progression-free survival and overall survival were 11.6 ± 0.4 and 18.1 ± 3.6 months
respectively. Six patients with a median follow-up of 19.8 months (9.6–41.0 months) were still alive and five of them had disease under control
with FL. Good responders (CR and good PR) had better survival than less satisfactory responders (PR and stable disease) (P = 0.05). From
Cox’s multivariate regression analysis, the only significant prognostic factor for survival was good response to MAP (P = 0.042). Liver
metastasis was the only significant variable in the best subset regression model that predicted good response to MAP (CR and good PR)
(P = 0.027). MAP was an effective combination for metastatic NPC with minimal stomatitis and cisplatin-related toxicity but had significant
myelosuppression. Weekly FL was a maintenance therapy with minimal side-effects. The response rate and overall survival of MAP-FL were
better than series previously reported even when a subset of patients with poor prognosis was selected. MAP-FL’s role as neoadjuvant or
adjuvant therapy is worthy of further study.
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the original protocols for treatment of head and neck squamous
cell carcinoma (Kohno et al, 1991; Osoba et al, 1992). Greater
than additive cytotoxicity has also been observed for combinations
of doxorubicin and cisplatin in multiple experimental system
(Drewinko et al, 1976). 5-FU has moderate activity for head and
neck squamous cell carcinoma. Its combination with leucovorin,
FL is a common treatment for many cancers (Grem et al, 1987). In
our institution, a significant portion of NPC patients with metas-
tasis have responded to weekly FL (unpublished data). The admin-
istration of weekly FL is convenient and the toxicity is minimal.
Based on the above considerations, we designed a sequential
MAP-FL combination protocol for a phase II study. MAP was
used for initial induction, aimed especially at hypoxic cells that
may have relative drug resistance, as extensive metastasis and
huge tumours are very common in NPC (Su et al, 1993). After
achieving remission, MAP was followed by weekly administration
of FL for maintenance, which took advantage of different action
mechanisms and minimal accumulated toxicity. We selected
patients with liver and/or lung metastasis, a sub-population with
measurable lesions and worst outcome to test feasibility and
efficacy.
PATIENTS AND METHODS
Patient eligibility
From October 1993 to June 1997, 32 consecutive patients with
measurable metastatic liver or lung lesions from NPC were
entered onto this phase II study. These patients had histologically
confirmed NPC at the primary site. Patients with bone metastasis
only were not included because of the difficulty of confirmation
and measurability. All patients had a Karnofsky performance scale
of 60% or better. Adequate bone marrow function (leucocyte count
³ 3500 ml–1, platelet count ³ 100 000 ml–1), liver function (total
bilirubin ≤ 2.0 mg dl–1) and renal function (serum creatinine
≤ 2.0 mg dl–1) were required. Written informed consents were
obtained from study patients.
Pretreatment work-up
The pretherapeutic work-up included a review of patient’s clinical
history and a physical examination, head and neck examination
and endoscopy, biochemical profile (SMA 12), complete blood
cell (CBC) count, erythrocyte sedimentation rate, lactate dehydro-
genase, EBV serology (immunoglobulin G [IgG] and IgA),
anti-viral capsid antigen (VCA) and early antigen (EA), head and
neck computerized tomographic (CT) scan, chest X-ray, bone
scintigraphy, abdominal sonography and/or CT scan, and other
tests indicated by the clinical picture. This work-up was repeated
after two courses of MAP and every 2 months thereafter. Blood
chemistries and blood counts were taken before each course to
assess renal and haematological toxicity.
Chemotherapy
The MAP chemotherapy consisted of intravenous administration
of mitomycin C 8 mg m–2, doxorubicin 40 mg m–2 and cisplatin
60 mg m–2 on day 1 with hydration and diuresis. Serotonin
antagonist and steroids were routinely given for prophylaxis of
nausea and vomiting. The cycle was repeated every 3 weeks if
haemogram measurements were adequate (leucocyte count
³ 3500 ml–1 and platelet count ³ 100 000 ml–1). If leucocyte count
was between 3000 and 3500 ml–1 or platelet count between 75 000
and 100 000 ml–1 on day 28, the subsequent cycle was modified to
a 20% reduction in the dose of mitomycin C and doxorubicin. If
leucocyte count was ≤ 3000 ml–1 and platelet count ≤ 75 000 ml–1
on day 28, MAP was withheld until haemogram recovered, then
therapy was resumed with a 25% reduction of the dose. MAP was
used for induction of remission and a maximum of four courses
was given. After MAP, patients were maintained with weekly FL
until disease progression. 5-FU 450 mg m–2 and leucovorin
30 mg m–2 were given weekly. FL was withheld if leucocyte count
was ≤ 2500 ml–1 or if there was any evidence of more than grade 2
mucositis or diarrhoea. Cases which had experienced grade 4 non-
haematologic toxicity and already achieved a partial response to
MAP were allowed to shift to weekly FL before completing four
courses of MAP. Cisplatin-containing regimens were used as
salvage therapy if disease progression during weekly FL was
noted.
Because of the extensive metastasis, radiation was not given to
the primary site for those cases with metastasis at initial diagnosis
of NPC.
Toxicity and measurement of response
All toxicities were evaluated at each course of MAP according to
the Eastern Cooperative Oncology Group criteria. The evaluation
for response was performed with a complete work-up 3 weeks
after the second course according to standard World Health
Organization (WHO) criteria. Complete response (CR) was
defined as disappearance of all detectable malignant disease with
no lesion for at least 4 weeks. Partial response (PR) was defined as
a more than 50% reduction in the sum of the products of the
greatest perpendicular dimensions for all measurable lesions for at
least 4 weeks, without new lesions. After chemotherapy, cases
with large tumours frequently had only equivocal residual disease
in image studies so we optionally defined this condition as good
PR. Stable disease (SD) was defined as a decrease of less than
50% or an increase of less than 25% over original measurements
of all known lesions.
Statistical analysis
The survival curves were estimated using the Kaplan–Meier
product-limit method (Kaplan and Meier, 1958) Difference
between survival curves was tested using the Mantel–Cox log-
rank test (Mantel, 1966). The relationship between survival and
potential explanatory factors was determined using the Cox
proportional hazard technique. The stepwise inclusion procedure
was used to determine the statistically significant prognostic
factors. The combination of independent variables predicting good
response to MAP-FL was evaluated by best subsets regression
with software SigmaStat (Jandel Scientific Software).
RESULTS
Patient characteristics
A total of 32 patients were included in this study. The characteris-
tics of the patients are summarized in Table 1. Thirty-one cases
were WHO type II or III in histology. Three cases presented with
metastatic disease upon diagnosis of NPC. Cases with lung or liver1964 RL Hong et al
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metastasis were 21 and 18 respectively. Fourteen cases had more
than one organ involvement. Twenty-one cases had more than five
metastatic lesions and 12 cases had largest tumour diameters of
more than 5 cm. Twenty-six cases showed at least one of these two
features of advanced disease. The mean lactate dehydrogenase
(LDH) level was 1030 U l–1 (270–3350) (normal 230–460), and 20
cases had abnormally high LDH levels. Three patients had prior
exposure to cisplatin or mitoxantrone as part of induction or
adjuvant chemotherapy.
Toxicity of MAP
One hundred and five cycles of MAP were administered to 32
patients. The mean dosages given were 96.0 ± 7.5, 96.0 ± 5.4 and
97.3  ± 5.6 (mean ± s.d.) of planned doses for mitomycin C,
doxorubicin and cisplatin respectively. Nausea and vomiting was
generally not severe with the prophylaxis of a serotonin antagonist
(Table 2). Stomatitis was common, but only 5% of the courses
were accompanied by grade 3 and 0% accompanied by grade 4
stomatitis, even though the majority of cases had previously
received radiation of 7000 cGy to the nasopharynx and neck. The
major toxicity was myelosuppression, and 40% and 13% of
courses had grades 3 and 4 leukopenia respectively. Two severe
infection episodes occurred during MAP chemotherapy and one of
them died of sepsis. Another case had haemolytic uraemic
syndrome related to the use of mitomycin C, which subsided after
appropriate treatment. No grade 3 or 4 cisplatin-related toxicity
was observed.
Response to MAP
The response results are summarized in Table 3. Of the 32 patients
studied, two (6%) CR, nine (28%) good PR, and 19 (59%) PR
were observed with an overall response rate of 94% (95% CI
Table 1 Patient characteristics
Characteristics No
Patient number 32
Age (years) 44.8 (22–64)
Sex (male:female) 28.4
Karnofsky performance scale
60 2
70 5
80 8
90 17
Histology (WHO type)
I1
II 9
III 22
Organ involved
Lung 21
Liver 18
Bone 6
Bone marrow 2
More than one organ 14
Lesion numbers
< 5 11
5–9 6
10–15 15
Largest tumour diameter (cm)
<5 20
5–12 12
Table 2 Frequecy of toxicity of MAP combination chemotherapy in 105
courses to 32 patients
Toxicity (%) Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Nausea 39 23 27 11 0
Vomiting 44 19 33 4 0
Stomatitis 69 10 16 5 0
Diarrhoea 87 6 5 2 1
Alopecia 13 9 78 0 0
Leukopenia 12 10 24 40 13
Thrombocytopenia 59 14 12 11 3
Hepatotoxicity 84 10 5 0 1
Nephrotoxicity 87 11 1 0 1a
Infection 84 6 5 4 2
a Haemolytic uraemic syndrome.
Table 3 Response rate to MAP in metastatic NPC
Number % 95% confidence interval
RR 30 94 84.9–100
CR 2 6 0.0–15.2
Good PR 9 28 11.7–44.6
PR 19 59 41.4–77.4
SD 2 6 0.0–15.2
PD 0 0 0.0–0.0
RR: response rate; CR: complete remission; PR: partial remission; SD:
stable disease; PD: progressive disease; good PR: only equivocal lesion(s)
remained in image study.
Table 4 Best model predicting response to MAP from best subsets regression
Variablea Coefficient Standard error t Statistic P-value Variance inflation factor
Constant –0.630 0.736 –0.856 0.399 0.000
Liver 0.365 0.156 2.340 0.027 1.127
Alb 0.304 0.181 1.677 0.105 1.193
LDH –0.00018 0.000105 –1.716 0.098 1.490
TTR –0.000173 0.000123 –1.413 0.169 1.415
*R squared = 0.365, adjusted R square = 0.271. aVariables used including age, sex, performance status, metastatic sites, tumour diameter, haemoglobin,
albumin, LDH, time to tumour relapse after radiotherapy (TTR).MAP-FL for metastatic NPC 1965
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84.9–100%). Two cases were categorized as stable disease and no
case had disease progression during MAP.
By best subsets regression, liver metastasis was the only signifi-
cant variable in the best subset model that predicted good response
to MAP (CR and good PR; P = 0.027, Table 4). All metastatic
lesions in liver responded well to MAP, but the duration of
response maintained by weekly FL varied greatly, which is
reflected on the wide variation of progression-free periods
(Figure 1). Serum LDH level, although generally accepted to
reflect the tumour burden, did not correlate with response to MAP.
Time to tumour relapse after radiotherapy, theoretically related to
the rate of tumour growth, also did not correlate with response.
Maintenance treatment with FL and survival
Excluding two cases with SD, one case with haemolytic uraemic
syndrome, one case died of sepsis and another case shifted to
usage of traditional herb drug, 27 cases entered the weekly FL
maintenance phase. The median duration of maintenance with
weekly FL was 38 weeks (8–91 weeks). There was no grade 3 or 4
toxicity noted during weekly FL. Three patients were still in
remission with treatment of weekly FL for 13, 14 and 21 months
respectively. Three deaths occurred while the diseases were still in
remission, but were not chemotherapy-related. Two patients died
of choking and aspiration pneumonia at 3 and 15 months of
weekly FL therapy, very likely due to poor upper aerodigestive
tract function, which is a common chronic side-effect of radio-
therapy for NPC. Another patient, with disease at good remission
for 2 years, died of vertebra-basilar artery ischaemia, which was
thought to be a complication of radiation.
The progression-free survival, overall survival and disease-
specific survival are shown in Figure 1 and the medians were
11.6  ± 0.4, 18.1 ± 3.6 and 19.9 ± 0.3 months respectively. Six cases
with a median follow-up of 19.8 months (9.6–41.0 months) were
still alive. In addition to the three cases maintained in remission
with FL, two cases once had disease progression due to interrup-
tion of FL treatment, still had disease under control with weekly
FL and had already survived 25 and 41 months respectively.
None of the six cases whose disease progressed within 4 months
of weekly FL responded to salvage cisplatin-based chemotherapy.
In contrast, among the ten cases with FL maintenance for at least
4 months, eight of them responded to cisplatin-based therapy at
disease progression (P = 0.066 by Fisher’s exact test).
Good responders (CR and good PR) to MAP had better survival
than less satisfactory responders (PR and stable disease) (P = 0.05,
Figure 2). Using Cox’s proportional hazard model for multivariate
analysis, including age, sex, performance status, metastatic sites,
tumour diameter, haemoglobin, albumin, LDH, response to MAP
and courses of MAP as independent variables, the only statistically
significant factor for survival was good response to MAP
(P = 0.042). Metastatic sites or tumour load which was reflected
by LDH and tumour diameter did not correlate with survival.
DISCUSSION
The previously reported response rates of metastatic NPC to
cisplatin-based chemotherapy ranged from 40% to 83.8% and the
complete remission rate from 4% to 24.3%. The averaged
response rate was 59.6% (95% CI 54–65%) and the CR rate was
17.6% (95% CI 13.3–21.9%) (Table 5) (Decker et al, 1983;
Boussen et al, 1991; Choo et al, 1991; Cvitkovic et al, 1991;
Mahjoubi et al, 1992; Gebbia et al, 1993; Su et al, 1993; Chi et al,
1994, 1995; Yeo et al, 1996; Fountzilas et al, 1997). Cases with
complete remission had relatively long survival, especially cases
with bone metastasis (Cvitkovic et al, 1991; Su et al, 1993), but the
prognosis of non-responders were grave (Hsu et al, 1983). The
median survival, available only from a limited number of reports,
ranged from 11.4 months to 16 months. How to further increase
response rate and how to decrease toxicity of treatment are impor-
tant issues.
The results of the present study were quite encouraging.
Compared with previously reported series, MAP-FL had a signifi-
cantly higher response rate and the longest median survival
reported to date (Table 5), even though we selected a subset of
patients with large tumour burden and unfavourable metastatic
sites. All cases with liver metastasis achieved good response with
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Figure 1 Kaplan–Meier plots of progression-free survival (curve A),
disease-specific survival (curve B) and overall survival (curve C) of 32
patients with metastatic NPC who received MAP induction and weekly FL for
maintenance
Figure 2 Kaplan–Meier plots of survival grouped by response to MAP as
good response (CR plus good PR; curve A) versus less satisfactory
response (PR plus SD; curve B). The difference between these two curves
was tested by Mantel–Cox log-rank test (P = 0.05)1966 RL Hong et al
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MAP and liver metastasis was the only significant variable to
predict good response to MAP. From a previous larger series, the
mean survival time for liver and lung metastases were 5.4 ± 0.5
months (mean ± standard error), and 11.8 ± 1.8 months respec-
tively (Hsu et al, 1983). In the present study, the mean survival for
cases with liver and lung metastasis was 19.3 ± 7.7 and 19.6 ± 4.7
months respectively. Response to chemotherapy was the only
significant prognostic factor and there was no difference in
survival with respect to metatastic sites and tumour burdens. A
more effective therapy may change the prognostic factors defined
from series treated with less active protocols.
In the present study, the toxicity of MAP was acceptable.
Grades 3 and 4 stomatitis were lower compared to those
commonly observed more than 80% seen in PF for head and neck
cancers (Dreyfuss et al, 1990; Vokes et al, 1990; Chi et al, 1994).
Furthermore, with a lower dosage of cisplatin and fewer courses of
cisplatin-based chemotherapy, nephrotoxicity, ototoxicity and
neurotoxicity were minimal. However, the myelotoxicity of MAP
was significantly higher. Use of mitomycin C accounted for the
accumulated myelotoxicity and haemolytic uraemic syndrome.
Reducing the courses of MAP and shifting to weekly FL earlier
may help to ameliorate myelotoxicity. The number of MAP
courses did not significantly influence the outcome or survival, but
MAP was very effective in quickly reducing tumour load, espe-
cially for cases with particularly heavy tumour loads. The median
duration of remission maintained by weekly FL was 38 weeks. Not
including three disease-free cases died of radiation-related toxi-
city, five of the 27 cases entered FL had disease maintained in SD
or in remission with a median of 14.5 months. There were no grade
III or IV toxicities noted during FL therapy. Considering the low
toxicity and reasonable activity, weekly FL was a good main-
tenance therapy.
Several new chemotherapeutic drugs are now available, but the
data concerning their activity in NPC is extremely lacking. Use of
single agent paclitaxel and combination paclitaxel and cisplatin
showed an unsatisfactory response rate (Table 5) (Au et al, 1996;
Fountzilas et al, 1997). Cisplatin, which is inexpensive and
effective, is still the cornerstone for treatment of metastatic NPC.
New drugs or new combination developments in treating NPC
should be aimed at reducing side-effects, especially accumulated
toxicity.
The approach in the present study of using MAP for induction
and weekly FL for maintenance had a satisfactory high response
rate and longer remission periods than those reported from
previous studies. The synergism between mitomycin C, doxoru-
bicin and cisplatin might have contributed to the high response rate
noted in our study. Maintenance with weekly FL may generally
reduce the toxicity of cisplatin-based combinational chemo-
therapy. This protocol is effective, inexpensive and feasible for
outpatient therapy. We are now conducting a clinical trial to incor-
porate this treatment into the initial treatment of advanced NPC,
hoping to improve overall survival.
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